Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses SHASTA-3 and SHASTA-4 12-Month Results for Plozasir

Arrowhead Pharmaceuticals NASDAQ: ARWR presented 12-month results from its Phase 3 SHASTA-3 and SHAS

RBC Capital analyst Luca Issi reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Outperform and mai

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today presented results from the pivotal Phase 3 SHAST

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented results from the pivotal Phase 3 SHAS

PASADENA, Calif.--(BUSINESS WIRE)-- #arrowheadpharma--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will present important new dat

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced th

Deutsche Bank AG purchased a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) in the unde

REDEMPLO® (plozasiran) is listed in the Lauer-Taxe® database as an adjunct to diet to reduce triglyc

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced th

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Arrowhead Pharma (NASDAQ:ARWR) with

Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2026 Earnings Call Transcript

Arrowhead Pharmaceuticals NASDAQ: ARWR reported positive Phase III results for plozasiran in severe

Arrowhead Pharma (NASDAQ:ARWR) reported quarterly losses of $(1.36) per share which missed the analy

SNDA to seek approval to expand the approved indication to include patients with severe hypertriglyc

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today an

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today an

California State Teachers Retirement System raised its stake in Arrowhead Pharmaceuticals, Inc. (NAS

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today an

B. Riley Securities analyst Madison El-Saadi maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

[url="]Arrowhead Pharmaceuticals, Inc.[/url] (NASDAQ: ARWR) today announced that it has completed en

Wall Street analysts changed outlook on top names. See all rating changes on Benzinga's analyst

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed enrollment in t

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today an

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Arrowhead Pharma (NASDAQ:ARWR) with

Affinity Asset Advisors LLC lifted its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ: A

California Public Employees Retirement System purchased a new position in shares of Arrowhead Pharma

Morgan Stanley analyst Michael Ulz maintains Arrowhead Pharma (NASDAQ:ARWR) with a Overweight and

Piper Sandler analyst Edward Tenthoff reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Overweight

Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and raises

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) stock is trading higher on Wednesday as the company rev

The latest Arrowhead drug study showed positive results, with significant triglyceride and pancreati

Arrowhead Pharmaceuticals surged nearly 20% after strong Phase 3 results for plozasiran in severe hy

Gainers Advanced Biomed (NASDAQ:ADVB) shares moved upwards by 108.6% to $14.77 during Wednesday&#39

Stocks split as oil climbs on the 11th night of Iran strikes and Super Micro rockets 26% on a record

U.S. stocks traded mostly higher midway through trading, with the Dow Jones index gaining more than

Arrowhead Pharmaceuticals reported positive phase 3 results for Redemplo, achieving 79-81% triglycer

Dow Jones up 200 pts, CME Group shares rise on upbeat earnings. Super Micro Computer, Arrowhead Phar

Gainers InMed Pharmaceuticals (NASDAQ:INM) stock moved upwards by 66.8% to $2.57 during Wednesday&#

[url="]Arrowhead Pharmaceuticals, Inc.[/url] (NASDAQ: ARWR) today announced topline results for the

Statistically significant reduction in acute pancreatitis events versus placebo across the entire sH

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today an

JP Morgan analyst Brian Cheng maintains Arrowhead Pharma (NASDAQ:ARWR) with a Overweight and rais

Analysts changed outlook on top names, including RXO, AMBQ, BE, ARWR, FSLR. See ratings page for upg

Stifel analyst James Condulis initiates coverage on Arrowhead Pharma (NASDAQ:ARWR) with a Buy rat

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) wit

US stock futures up, Nasdaq 100 gains 1%. Biohaven (BHVN) shares down after BofA downgrade and enrol

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that the European Commission (EC) has